Express Pharma
SEPTEMBER 13, 2024
Also, to establish a sense of transparency, especially for audits, and adhere to regulatory standards, manufacturers must have a Quality Management System (QMS) in place. This system assists in proper documentation and record-keeping.
STAT
FEBRUARY 27, 2024
antitrust regulators into pharmaceutical industry middlemen has been stymied because the companies have failed to provide many of the documents that, in some cases, were requested as far back as June 2022. A much-anticipated inquiry by U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Commerce
MAY 12, 2024
This document outlines key strategies and testing protocols critical for optimizing EPCIS implementation, ensuring that pharmaceutical manufacturers can maintain compliance and operational efficiency.
Express Pharma
JUNE 12, 2024
With an impressive lineup of speakers and panelists, the summit promises deep insights into the evolving landscape of pharmaceutical manufacturing. The participants can gain deeper insights on recent focus areas such as Quality Management Maturity Models, Data and Documentation Imperative and Talent Capability Building.
Pharmaceutical Commerce
MAY 12, 2024
This document details the benefits of DataX, a revolutionary solution tailored for pharmaceutical manufacturers. Designed to navigate the complexities of managing serialized data for drop shipments, DataX ensures secure, compliant, and efficient data exchange.
European Pharmaceutical Review
FEBRUARY 22, 2023
The Parenteral Drug Association (PDA)’s long-awaited Technical Report 90: Contamination Control Strategy Development in Pharmaceutical Manufacturing is now available. Key features of the PDA TR 90 report The document addresses the evolution of contamination control principles towards a holistic approach.
European Pharmaceutical Review
AUGUST 23, 2022
Of the cGMP letters, three major types of violations – deficiencies in process validation, documentation practices (data integrity) and quality control – accounted for 26 percent, 21 percent and 15 percent of warning letters respectively. Overall, validation, documentation and quality control were the major cGMP violations.
Expert insights. Personalized for you.
104 
Let's personalize your content